[go: up one dir, main page]

AR076601A1 - PYRIMIDINS AS THERAPEUTIC AGENTS - Google Patents

PYRIMIDINS AS THERAPEUTIC AGENTS

Info

Publication number
AR076601A1
AR076601A1 ARP100101785A ARP100101785A AR076601A1 AR 076601 A1 AR076601 A1 AR 076601A1 AR P100101785 A ARP100101785 A AR P100101785A AR P100101785 A ARP100101785 A AR P100101785A AR 076601 A1 AR076601 A1 AR 076601A1
Authority
AR
Argentina
Prior art keywords
aromatic
nhc
unsubstituted
alkyl
independently
Prior art date
Application number
ARP100101785A
Other languages
Spanish (es)
Original Assignee
Chlorion Pharma Inc
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chlorion Pharma Inc, Univ Laval filed Critical Chlorion Pharma Inc
Publication of AR076601A1 publication Critical patent/AR076601A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de cualquiera de las Formulas ((1a-2)-(1a-21)), incluyendo otros tautomeros, estereoisomeros, estereoisomeros E/Z, profármacos, sales farmacéuticamente aceptables, y también caracteriza composiciones, métodos para tratar o prevenir dolor (por ej., dolor neuropático), inflamacion, o epilepsia y como anticonvulsivos. Reivindicacion 1: Un compuesto que tiene la siguiente estructura (1a) y sus tautomeros (1b), incluyendo otros tautomeros, estereoisomeros, estereoisomeros E/Z, profármacos y sus sales farmacéuticamente aceptables, donde Q1 es -O-, -S-, -SO-, -SO2-, -CH2-, -CH2CH2-, -CH=CH-, -OCH2-, -SCH2-, -SOCH2-, o -SO2CH2-; V es O, S, NH, o NZ, o amino ácido ligado a N-terminal, halogeno, o H cuando R1 está ausente; R1 está ausente, -H, alquilo C1-8, alquenillo C2-8, alquinilo C2-8, cicloalquilo C3-12, arilo C6-12, arilalquilo C7-14, -(CH2)nOZ, -C(O)Z, -C(O)OZ, -C(O)NHZ, -C(O)N(Z)2, -(CR1AR1B)r2OPO(OZ)2, -(CR2AR2B)r3PO(OZ)2, o aminoácido ligado a C-terminal; cada R1A, R1B, R2A y R2B es, de manera independiente, H o alquilo C1-5; cada Z es, de manera independiente, -H, alquilo C1-8, alqcicloalquilo C4-12, alqheterociclilo C3-9, donde el heterociclilo es de 3 a 9 miembros, cicloalquilo C3-12, arilo C6-12, arilalquilo C7-14, heterociclilo 3 a 9 miembros aromático o no aromático, alquenilo C2-8, o alquinilo C2-8, o dos Z, junto con el átomo(s) al cual cada uno está adherido, se juntan para formar un heterociclo de 3 a 7 miembros aromático o no aromático; cada n es 1 o 2; cada r2 es un numero entero entre 1-3; cada r3 es un numero entero entre 0-2; R2 y R3 son cada uno, de manera independiente, -H, -D, -OH, -halogeno, -CN, -NO2, -SH, -CF3, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, arilo C6-12, arilalquilo C7-14, heterociclilo de 3 a 9 miembros aromático o no aromático, -OZ, -N(Z)2, -C(NH)N(Z)2, -O(CH2)nOZ, -C(O)Z, -OC(O)Z, -OC(O)OZ, -OC(O)N(Z)2, -C(O)N(Z)2, -C(O)OZ, -SZ, -SOZ, -S(O)2Z, -NHC(O)Z, -NHS(O)2Z, -NHC(NH)N(Z)2, -NZC(NH)N(Z)2, - NHC(NCN)N(Z)2, -NZC(NCN)N(Z)2, o -PO(OZ)2, o R2 y R3, junto con el átomo al cual cada uno está adherido, se juntan para formar un carbociclo o heterociclo de 5 o 6 miembros aromático o no aromático; A1 y A2 son cada uno, de manera independiente, -H, -D, -halogeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, -arilo C6-12, o arilalquilo C7-14; A3 es un anillo heterocíclico aromático seleccionado entre el grupo integrado por los fragmentos A-1 a A-4; Q2, Q5 y Q6 son cada uno, de manera independiente, N, N+-O-, o C; Q3 y Q4 son cada uno, de manera independiente, N, N+-O-, C, O, o S, donde solamente uno de Q3 y Q4 puede ser O u S; donde Q2, Q3, Q4, Q5 y Q6 simultáneamente son C solo si R4 y R5, R5 y R6, R6 y R7, o R7 y R8, junto con los átomos al cual cada uno está adherido, se unen para formar un heterociclilo de 5 a 6 miembros aromático o no aromático; y R4, R5, R6, R7 y R8 son cada uno, de manera independiente, ausente, -H, -D, -OH, -O, -halogeno, -CN, -NO2, -SH, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, arilo C6-12, arilalquilo C7-14, heterociclilo de 3 a 9 miembros aromático o no aromático, -OZ, -N(Z)2, -C(NH)N(Z)2, -O(CH2)nOZ, -C(O)Z, -OC(O)Z, -OC(O)OZ, -OC(O)N(Z)2, -C(O)N(Z)2, -C(O)OZ, -SZ, -SOZ, -S(O)2Z, -NHC(O)Z, -NHS(O)2Z, -NHC(NH)N(Z)2, -NZC(NH)N(Z)2, -NHC(NCN)N(Z)2, -NZC(NCN)N(Z)2, -PO(OZ)2, o R4 y R5, o R5 y R6, o R6 y R7, o R7 y R8, junto con los átomos al cual cada uno está adherido, se unen para formar un carbociclo o heterociclo de 5 a 6 miembros aromático o no aromático siempre y cuando el sistema anular resultante no esté sustituido o bencimidazol no sustituido, no sustituido benzotiazol, imidazo[1,2-a]piridina no sustituido, 5- o 6- cloro-imidazo[1,2-a]piridina, indol cuando R2 es C(O)OCH2CH3, quinolina no sustituido, quinolina 8-sustituida, quinoxalina no sustituido, 2- o 4-cloro-quinolina, 2-cloro-7-metil-quinolina o 2-piperidin-1-il-quinolina cuando R3 es NH2, o 4-hidroxi-1,3-quinazolina, donde cuando A3 es piridina-2-il no sustituido y A1, y A2 son cada uno -H, R3 no es -H, -OH, -NH2, -CF3, alquilo C1-3, fenilo, difluorobencil, -NHC(O)furan, -NHC(O)CH3, o -NHC(O)CH2CH3; donde cuando A3 es piridina-4-il no sustituido y A1 y A2 son cada uno -H, R3 no es -H, -OH, -NH2, -CH3, -CH2CH2CH3, o difluorobencil; donde cuando A3 es no sustituido, 6-cloro, o 2,6-dicloro piridina-3-il y A1 y A2 son cada uno -H, R3 no es -H, -OH, -NH2, -CF3, alquilo C1-3, fenilo, -C(O)OCH2CH3, o -NHC(O)CH3; donde cuando A3 es pirazol-1-il sustituido o no sustituido, R3 no es -OH; y donde A3 no es 4-NO2-imidazol-2-il.A compound of any of the Formulas ((1-2) - (1-21)), including other tautomers, stereoisomers, E / Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and also characterizes compositions, methods for treating or preventing pain ( eg, neuropathic pain), inflammation, or epilepsy and as anticonvulsants. Claim 1: A compound having the following structure (1a) and its tautomers (1b), including other tautomers, stereoisomers, E / Z stereoisomers, prodrugs and their pharmaceutically acceptable salts, wherein Q1 is -O-, -S-, - SO-, -SO2-, -CH2-, -CH2CH2-, -CH = CH-, -OCH2-, -SCH2-, -SOCH2-, or -SO2CH2-; V is O, S, NH, or NZ, or N-terminal linked amino acid, halogen, or H when R1 is absent; R1 is absent, -H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-12 cycloalkyl, C6-12 aryl, C7-14 arylalkyl, - (CH2) nOZ, -C (O) Z, -C (O) OZ, -C (O) NHZ, -C (O) N (Z) 2, - (CR1AR1B) r2OPO (OZ) 2, - (CR2AR2B) r3PO (OZ) 2, or C-linked amino acid -terminal; each R1A, R1B, R2A and R2B is, independently, H or C1-5 alkyl; each Z is, independently, -H, C1-8 alkyl, C4-12 alkylcycloalkyl, C3-9 alkylheterocyclyl, where the heterocyclyl is 3 to 9 members, C3-12 cycloalkyl, C6-12 aryl, C7-14 arylalkyl , 3 to 9 aromatic or non-aromatic heterocyclyl members, C2-8 alkenyl, or C2-8 alkynyl, or two Z, together with the atom (s) to which each is attached, join to form a 3 to 7 heterocycle aromatic or non-aromatic members; each n is 1 or 2; each R2 is an integer between 1-3; each r3 is an integer between 0-2; R2 and R3 are each, independently, -H, -D, -OH, -halogen, -CN, -NO2, -SH, -CF3, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-12 cycloalkyl, C6-12 aryl, C7-14 arylalkyl, 3- to 9-membered aromatic or non-aromatic heterocyclyl, -OZ, -N (Z) 2, -C (NH) N (Z) 2, -O ( CH2) nOZ, -C (O) Z, -OC (O) Z, -OC (O) OZ, -OC (O) N (Z) 2, -C (O) N (Z) 2, -C ( O) OZ, -SZ, -SOZ, -S (O) 2Z, -NHC (O) Z, -NHS (O) 2Z, -NHC (NH) N (Z) 2, -NZC (NH) N (Z ) 2, - NHC (NCN) N (Z) 2, -NZC (NCN) N (Z) 2, or -PO (OZ) 2, or R2 and R3, together with the atom to which each is attached, together to form an aromatic or non-aromatic 5 or 6-membered carbocycle or heterocycle; A1 and A2 are each, independently, -H, -D, -halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-12 cycloalkyl, C6-12 aryl, or C7 arylalkyl- 14; A3 is an aromatic heterocyclic ring selected from the group consisting of fragments A-1 to A-4; Q2, Q5 and Q6 are each, independently, N, N + -O-, or C; Q3 and Q4 are each, independently, N, N + -O-, C, O, or S, where only one of Q3 and Q4 can be O or S; where Q2, Q3, Q4, Q5 and Q6 simultaneously are C only if R4 and R5, R5 and R6, R6 and R7, or R7 and R8, together with the atoms to which each is attached, join to form a heterocyclyl of 5 to 6 aromatic or non-aromatic members; and R4, R5, R6, R7 and R8 are each, independently, absent, -H, -D, -OH, -O, -halogen, -CN, -NO2, -SH, C1-8 alkyl, alkenyl C2-8, C2-8 alkynyl, C3-12 cycloalkyl, C6-12 aryl, C7-14 arylalkyl, 3- to 9-membered aromatic or non-aromatic heterocyclyl, -OZ, -N (Z) 2, -C (NH) N (Z) 2, -O (CH2) nOZ, -C (O) Z, -OC (O) Z, -OC (O) OZ, -OC (O) N (Z) 2, -C (O) N (Z) 2, -C (O) OZ, -SZ, -SOZ, -S (O) 2Z, -NHC (O) Z, -NHS (O) 2Z, -NHC (NH) N (Z) 2 , -NZC (NH) N (Z) 2, -NHC (NCN) N (Z) 2, -NZC (NCN) N (Z) 2, -PO (OZ) 2, or R4 and R5, or R5 and R6 , or R6 and R7, or R7 and R8, together with the atoms to which each is attached, join to form an aromatic or non-aromatic 5 to 6-membered carbocycle or heterocycle as long as the resulting ring system is not substituted or unsubstituted benzimidazole, unsubstituted benzothiazole, unsubstituted imidazo [1,2-a] pyridine, 5- or 6- chloro-imidazo [1,2-a] pyridine, indole when R2 is C (O) OCH2CH3, unsubstituted quinoline , 8-substituted quinoline, unsubstituted quinoxaline, 2- or 4-chloro-quin oline, 2-chloro-7-methyl-quinoline or 2-piperidin-1-yl-quinoline when R3 is NH2, or 4-hydroxy-1,3-quinazoline, where when A3 is unsubstituted pyridine-2-yl and A1 , and A2 are each -H, R3 is not -H, -OH, -NH2, -CF3, C1-3 alkyl, phenyl, difluorobenzyl, -NHC (O) furan, -NHC (O) CH3, or -NHC (O) CH2CH3; where when A3 is unsubstituted pyridine-4-yl and A1 and A2 are each -H, R3 is not -H, -OH, -NH2, -CH3, -CH2CH2CH3, or difluorobenzyl; where when A3 is unsubstituted, 6-chloro, or 2,6-dichloro pyridine-3-yl and A1 and A2 are each -H, R3 is not -H, -OH, -NH2, -CF3, C1- alkyl 3, phenyl, -C (O) OCH2CH3, or -NHC (O) CH3; where when A3 is substituted or unsubstituted pyrazol-1-yl, R3 is not -OH; and where A3 is not 4-NO2-imidazol-2-yl.

ARP100101785A 2009-05-21 2010-05-21 PYRIMIDINS AS THERAPEUTIC AGENTS AR076601A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18025309P 2009-05-21 2009-05-21
US28500309P 2009-12-09 2009-12-09
US28962809P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
AR076601A1 true AR076601A1 (en) 2011-06-22

Family

ID=43124965

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101785A AR076601A1 (en) 2009-05-21 2010-05-21 PYRIMIDINS AS THERAPEUTIC AGENTS

Country Status (6)

Country Link
US (2) US9040538B2 (en)
EP (1) EP2432776B1 (en)
AR (1) AR076601A1 (en)
CA (1) CA2762680C (en)
TW (1) TW201100411A (en)
WO (1) WO2010132999A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076601A1 (en) 2009-05-21 2011-06-22 Chlorion Pharma Inc PYRIMIDINS AS THERAPEUTIC AGENTS
EP2523661B1 (en) 2010-01-15 2017-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Nkcc inhibitors for the treatment of autism
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
CN102070553B (en) * 2010-12-17 2013-08-07 西安瑞联近代电子材料有限责任公司 Synthesis method of thiazole-4-formaldehyde
EP2707373A1 (en) 2011-05-10 2014-03-19 Bayer Intellectual Property GmbH Bicyclic (thio)carbonylamidines
EP2729476B1 (en) 2011-07-06 2017-08-23 Bayer Intellectual Property GmbH Heteroaryl substituted pyrazolopyridines and their use as stimulators of soluble guanylate cyclase
DE102012200354A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh New heteroaryl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
CN103857657B (en) 2011-08-18 2016-04-20 日本新药株式会社 Hete rocyclic derivatives and medicine
DE102012200360A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted triazines and their use
DE102012200349A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted fused pyrimidines and triazines and their use
EP2822951B1 (en) 2012-03-06 2017-07-26 Bayer Intellectual Property GmbH Substituted azabicycles and use thereof
EP2732815A1 (en) 2012-11-16 2014-05-21 Neurochlore Modulators of intracellular chloride concentration for treating fragile X syndrome
WO2014139983A1 (en) 2013-03-13 2014-09-18 H. Lundbeck A/S [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors
KR20150142014A (en) 2013-04-12 2015-12-21 바이엘 크롭사이언스 악티엔게젤샤프트 Novel triazole derivatives
WO2014167010A1 (en) 2013-04-12 2014-10-16 Bayer Cropscience Ag Novel triazole derivatives
US9550752B2 (en) 2013-04-12 2017-01-24 Bayer Cropscience Aktiengesellschaft Triazolinthione derivatives
MX360455B (en) 2013-05-14 2018-11-01 Active Biotech Ab N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors.
MX2016000258A (en) 2013-07-10 2016-04-28 Bayer Pharma AG Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof.
CN104693114B (en) * 2013-12-10 2019-08-16 四川海思科制药有限公司 A kind of improved preparation method of betrixaban
RU2537848C1 (en) * 2013-12-10 2015-01-10 Федеральное государственное казенное учреждение "33 Центральный научно-исследовательский испытательный институт Министерства обороны Российской Федерации" Method of obtaining 2-chloro-5-hydroxymethylpyridine
US9510593B2 (en) * 2014-01-17 2016-12-06 Valent Biosciences Corporation S-benzylthiouracil compounds and methods of enhancing plant root growth
US10525024B2 (en) 2014-08-15 2020-01-07 The Johns Hopkins University Methods for rescuing phenobarbital-resistance of seizures by ANA-12 or ANA-12 in combination with CLP290
CN113121450A (en) 2014-08-29 2021-07-16 Tes制药有限责任公司 Alpha-amino-beta-carboxymuconate semialdehyde decarboxylase inhibitors
CN104478795A (en) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 Preparation method of 2-chloro nicotinaldehyde
WO2016156294A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Triazol derivatives as fungicides
PE20180175A1 (en) 2015-04-02 2018-01-22 Bayer Cropscience Ag NEW 5-SUBSTITUTED IMIDAZOLYL METHYL DERIVATIVES
UY36949A (en) 2015-10-14 2017-04-28 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware 2,4-DIHIDROXI-NICOTINAMIDS AS APJ AGONISTS
CA3008630A1 (en) 2015-12-16 2017-06-22 Bristol-Myers Squibb Company Heteroarylhydroxypyrimidinones as agonists of the apj receptor
AU2017238504B2 (en) 2016-03-24 2021-05-27 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
KR20190026902A (en) 2016-07-14 2019-03-13 화이자 인코포레이티드 Novel pyrimidinecarboxamide as an inhibitor of vanin-1 enzyme
CN109843065A (en) 2016-09-13 2019-06-04 拜耳作物科学股份公司 Active agent combinations comprising the 5- imdazole derivatives replaced
WO2018060073A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazole derivatives
BR112019006450A2 (en) 2016-09-29 2019-06-25 Bayer Cropscience Ag new 5-substituted imidazolylmethyl derivatives
US20200045972A1 (en) 2016-09-29 2020-02-13 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
CN106946772B (en) * 2016-11-02 2019-08-06 河南省商业科学研究所有限责任公司 A kind of synthetic method of 2,2 '-bipyridyls -4,4 '-methyl formate
US12156523B2 (en) * 2017-03-17 2024-12-03 Mmag Co., Ltd. Plant disease control agent
ES2938335T3 (en) 2017-03-24 2023-04-10 St Pharm Co Ltd Novel pyrrolopyridine derivative, method of producing the same and use thereof
US11827616B2 (en) 2017-05-04 2023-11-28 Discovery Purchaser Corporation Heterocyclic compounds as pesticides
CN107286083A (en) * 2017-06-16 2017-10-24 康化（上海）新药研发有限公司 A kind of synthetic method of the pyridine carboxaldehyde of 2 chlorine, 6 bromine 3
JP2021502402A (en) 2017-11-13 2021-01-28 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Tetrazolylpropyl derivatives and their use as fungicides
US10300100B1 (en) 2018-09-27 2019-05-28 King Saud University Extract of Vicia faba beans
BR112022005463A2 (en) 2019-09-25 2022-06-14 Pfizer Polyheterocyclic sting modulators (interferon gene stimulator)
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CN118748993A (en) 2021-12-28 2024-10-08 日本新药株式会社 Indazole compounds and drugs
WO2023196614A1 (en) * 2022-04-08 2023-10-12 Axonis Therapeutics, Inc. Methods and compounds for treating neurological disorders
AU2024243715A1 (en) * 2023-04-05 2025-10-09 Axonis Therapeutics, Inc. Kcc2 potentiators and uses thereof
WO2024233885A2 (en) * 2023-05-11 2024-11-14 Axonis Therapeutics, Inc. Kcc2 potentiators and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3369514D1 (en) 1983-05-05 1987-03-05 Heumann Ludwig & Co Gmbh Pyrimidinethioalkyl pyridine derivatives, process for their preparation and medicines containing these compounds
HU203736B (en) 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
US5472967A (en) * 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
JPH06206805A (en) 1992-02-17 1994-07-26 Hisamitsu Pharmaceut Co Inc Tyrosinase inhibitor and external preparation for skin using the same
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
EP0728130A1 (en) * 1993-11-12 1996-08-28 PHARMACIA & UPJOHN COMPANY Pyrimidine-thioalkyl and alkylether compounds
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
UA56992C2 (en) * 1995-05-08 2003-06-16 Фармація Енд Апджон Компані a- pyrimidine-thioalkyl substituted and a- pyrimidine-oxo-alkyl substituted compounds
JP2001506666A (en) 1996-12-20 2001-05-22 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング Imidazopyridazine
AR023071A1 (en) 1998-12-23 2002-09-04 Syngenta Participations Ag PIRIDINCETONE COMPOUNDS, INTERMEDIATE COMPOUNDS, HERBICITY AND INHIBITOR COMPOSITION OF PLANTAGE GROWTH, METHOD FOR CONTROLLING INDESATED VEGETATION, METHOD FOR INHIBITING GROWTH OF PLANTS, AND USE OF COMPOSITION TO GROW GROWTH.
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GT200100103A (en) 2000-06-09 2002-02-21 NEW HERBICIDES
CA2443697A1 (en) 2001-04-13 2002-10-24 Pier F. Cirillo 1,4-disubstituted benzo-fused compounds
EP1392661A1 (en) 2001-05-16 2004-03-03 Boehringer Ingelheim Pharmaceuticals Inc. Diarylurea derivatives useful as anti-inflammatory agents
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
CA2446193C (en) 2001-06-05 2011-11-01 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
JP2003206230A (en) 2002-01-10 2003-07-22 Yamanouchi Pharmaceut Co Ltd Cyanoheterocyclic derivative or its salt
WO2004014870A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
SI1601653T1 (en) 2003-03-07 2009-06-30 Syngenta Participations Ag Process for the production of substituted nicotinic acid esters
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
JP2007502776A (en) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー 6-Substituted anilinopurines as RTK inhibitors
JP4534452B2 (en) * 2003-09-04 2010-09-01 株式会社クレハ 3-methylisothiazole-5-methanol derivative, process for producing the same, and agricultural and horticultural disease control
JP2007505050A (en) * 2003-09-12 2007-03-08 アルピダ エー／エス Isoxazoles as peptide deformylase inhibitors
PT1809624E (en) 2004-08-28 2014-01-14 Astrazeneca Ab Pyrimidine sulphonamide derivatives as chemokine receptor modulators
WO2006031852A1 (en) * 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2008516938A (en) * 2004-10-15 2008-05-22 アストラゼネカ アクチボラグ Substituted adenine and its use
CA2586334A1 (en) 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
CN101184493A (en) * 2005-03-04 2008-05-21 阿尔斯根公司 Treatment of amyotrophic lateral sclerosis with pyrimethamine and its analogs
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (en) 2005-04-06 2007-05-02 Astrazeneca Ab DERIVATIVES OF [1,3] TIAZOLO [4,5-D] PYRIMIDIN-2 (3H) -ONA 5,7-SUBSTITUTED
WO2006133353A2 (en) 2005-06-08 2006-12-14 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
CN101522687A (en) * 2006-01-30 2009-09-02 阿雷生物药品公司 Heterobicyclic thiophene compounds and methods of use
RU2522430C2 (en) * 2008-01-22 2014-07-10 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи 5-fluoropyrimidine derivatives as fungicides
WO2010027097A1 (en) 2008-09-04 2010-03-11 Mitsubishi Tanabe Pharma Corporation Tri-substituted pyrimidine compounds and their use as pde10 inhibitors
EP2342191B1 (en) * 2008-09-10 2013-03-20 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
AR076601A1 (en) 2009-05-21 2011-06-22 Chlorion Pharma Inc PYRIMIDINS AS THERAPEUTIC AGENTS

Also Published As

Publication number Publication date
US9315521B2 (en) 2016-04-19
EP2432776A4 (en) 2012-10-24
US20100298336A1 (en) 2010-11-25
CA2762680A1 (en) 2010-11-25
WO2010132999A1 (en) 2010-11-25
EP2432776A1 (en) 2012-03-28
US20150225423A1 (en) 2015-08-13
CA2762680C (en) 2018-04-17
TW201100411A (en) 2011-01-01
EP2432776B1 (en) 2019-09-11
WO2010132999A8 (en) 2011-06-30
US9040538B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
AR076601A1 (en) PYRIMIDINS AS THERAPEUTIC AGENTS
ES2975183T3 (en) ENPP1 inhibitors and their use for cancer treatment
KR102237707B1 (en) Derivatives replacing quinolones or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and applications thereof
JP2025098199A (en) Enpp1 inhibitors and methods of modulating immune response
Bregman et al. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors
ES2974334T3 (en) Heterocyclic ATR kinase inhibitors
AU760020B2 (en) Novel angiogenesis inhibitors
AR050788A1 (en) ENANTIOMERALLY PURE AMINOHETEROARILO COMPOUNDS AS PROTEIN QUINASE INHIBITORS
JP5656634B2 (en) Inhibitors of protein tyrosine kinase activity
PE20150218A1 (en) NEW PHOSPHATE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PE20090493A1 (en) DERIVATIVES OF 6-CYCLOAMINE-3- (PYRIDAZIN-4-IL) IMIDAZO [1,2-b] -PYRIDAZINE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
JP7341156B2 (en) Heterocyclic inhibitors of ATR kinase
CA2392971C (en) 2,4-diaminopyrimidine compounds useful as immunosuppressants
ES2734735T3 (en) 4-Oxo-3,4-dihydro-1,2,3, -benzotriazine derivatives as modulators of GPR139
AR053232A1 (en) CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM.
AR059246A1 (en) THIOPHENIC HETEROBICICLIC COMPOUNDS AND METHODS OF USE
PE20090960A1 (en) QUINAZOLINADIONE DERIVATIVES, ITS PREPARATION AND THEIR THERAPEUTIC APPLICATIONS
PE20030922A1 (en) PYRIDINE AND QUINOLINE DERIVATIVES
PE20061442A1 (en) HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA
RU2006139258A (en) KINAZ BENZOTRIAZINE INHIBITORS
EA024194B1 (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
ES2564010T3 (en) Pharmaceutical composition to treat or prevent glaucoma
PE20110835A1 (en) PYRIDYLOXY-INHIBITORS OF VEGF-R2 AND USE OF THE SAME FOR THE TREATMENT OF DISEASES
PE20170775A1 (en) CYTOTOXIC BENZODIAZEPINE DERIVATIVES
RU2011108024A (en) 3-azabicyclo (3.1.0) HEXIL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure